Morgan Stanley raised the firm’s price target on GSK to 1,830 GBp from 1,730 GBp and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- GSK confirms confidential settlement reached with Boyd/Steenvoord over Zantac
- GSK announces EAGLE-1 phase III trial met primary efficacy endpoint
- GSK announces LATITUDE phase III interim trial demonstrates ‘superior efficacy’
- GSK price target raised to 1,820 GBp from 1,650 GBp at Berenberg
- GSK completes acquisition of Aiolos Bio
